vimarsana.com

Latest Breaking News On - Pharmaceuticals price performance - Page 6 : vimarsana.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $21.00 at Mizuho

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $21.00 at Mizuho
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Canada
United-states
China
James-kihara
Stephen-davis
Pharmaceuticals-price-performance
China-universal-asset-management-co
Securities-exchange-commission
Quest-partners
Pharmaceuticals-inc
Legato-capital-management
Royal-bank

Oppenheimer Reiterates "Market Perform" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer Reiterates "Market Perform" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Switzerland
United-states
Canada
Swiss
Markc-schneyer
Stephen-davis
Royal-bank
Pharmaceuticals-inc
Sg-americas-securities
Securities-exchange-commission
Pharmaceuticals-price-performance
Needham-company

HC Wainwright Reiterates Buy Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN)

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN […]

Piper-sandler
Pharmaceuticals-price-performance
Pharmaceuticals-daily
Free-report
Get-free-report
Aslan-pharmaceuticals
Nasdaq-asln
Asln
Medical
Reiterated-rating
Hc-wainwright

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CEO Stephen Davis Sells 11,427 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) CEO Stephen Davis sold 11,427 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $193,573.38. Following the transaction, the chief executive officer now owns 155,231 shares of the company’s […]

Alger
Algeria
Canada
Mizuho
Sakhalinskaya-oblast
Russia
United-states
Robertw-baird
Stephen-davis
Pharmaceuticals-price-performance
Pharmaceuticals-company-profile
Pharmaceuticals-daily

ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $37.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on ACAD. Royal Bank of Canada decreased […]

Canada
United-states
America
Robertw-baird
Markc-schneyer
Brendan-teehan
Pharmaceuticals-inc
Charles-schwab-investment-management-inc
Securities-exchange-commission
Royal-bank
Jpmorgan-chase-co
Mutual-of-america-capital-management

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.